Recruiting × Urinary Bladder Neoplasms × 90 days × Clear all Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
Recruiting
5,950 enrolled
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Phase 2 Recruiting
111 enrolled
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 Recruiting
310 enrolled
FORAGER-2
Phase 3 Recruiting
450 enrolled
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
Phase 2 Recruiting
60 enrolled
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Phase 2 Recruiting
314 enrolled
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Phase 2 Recruiting
160 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Recruiting
105 enrolled
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
Phase NA Recruiting
360 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
ORI-EGI-03
Recruiting
450 enrolled
Bladder Bank (a Prospective Banking Study)
Recruiting
1,500 enrolled
MK-3475-04D
Phase 1/2 Recruiting
55 enrolled
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Phase 1 Recruiting
30 enrolled
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Phase 1 Recruiting
12 enrolled
EMPOWER
Phase NA Recruiting
100 enrolled
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Phase 2 Recruiting
148 enrolled
Evaluation for NCI Surgery Branch Clinical Research Protocols
Recruiting
7,000 enrolled
Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer
Phase 2 Recruiting
34 enrolled
A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer
Phase 1 Recruiting
294 enrolled
GUB-BCR-001
Recruiting
1,000 enrolled
Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy
Recruiting
1,000 enrolled
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Phase 2/3 Recruiting
470 enrolled
MOMENTUM
Recruiting
8,000 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
Telehealth Intervention for Ostomy Self-Management
Phase 2 Recruiting
150 enrolled
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2/3 Recruiting
630 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
GAIN-BCG
Phase 3 Recruiting
330 enrolled
OCCURORTW
Recruiting
2,000 enrolled
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
Recruiting
60 enrolled
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
Phase NA Recruiting
196 enrolled
A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
Phase NA Recruiting
128 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
Phase 2 Recruiting
18 enrolled
Intravesical Gem/Doce in Patients With NMIBC
Phase 2 Recruiting
25 enrolled
COMPETENCE
Phase NA Recruiting
140 enrolled
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Phase 2 Recruiting
64 enrolled
RIVERS
Recruiting
600 enrolled
DP-04
Recruiting
100 enrolled
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
Recruiting
400 enrolled
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
Phase 3 Recruiting
150 enrolled
MK-3120-003
Phase 1/2 Recruiting
45 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
Phase 1/2 Recruiting
159 enrolled
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
Phase 1 Recruiting
36 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
Recruiting
500 enrolled
Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Recruiting
180 enrolled